MS4A1 and non-Hodgkin lymphoma: The same chelating unit was then associated with the monoclonal antibody rituximab (149Tb-rituximab) for the targeting of CD20 receptors expressed at the surface of B cells in Non-Hodgkin Lymphoma (NHL) or chronic lymphocytic leukemia.